Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2922719 | 0.83 | DNM1 (0.40) | HTTEPHX2NAAACES2CES1 | |
| SCHEMBL6288219 | 0.83 | DNM1 (0.40) | HTTEPHX2NAAACES2CES1 | |
| SCHEMBL3813028 | 0.83 | DNM1 (0.40) | HTTEPHX2NAAACES2CES1 | |
| SCHEMBL6288242 | 0.83 | DNM1 (0.40) | HTTEPHX2NAAACES2CES1 | |
| SCHEMBL27765995 | 0.83 | DNM1 (0.40) | HTTEPHX2NAAACES2CES1 | |
| SCHEMBL6288656 | 0.83 | DNM1 (0.40) | HTTEPHX2NAAACES2CES1 | |
| SCHEMBL6288234 | 0.83 | DNM1 (0.40) | HTTEPHX2NAAACES2CES1 | |
| SCHEMBL15659895 | 0.83 | DNM1 (0.40) | HTTEPHX2NAAACES2CES1 | |
| SCHEMBL49664 | 0.83 | DNM1 (0.40) | HTTEPHX2NAAACES2CES1 | |
| SCHEMBL6291671 | 0.83 | DNM1 (0.40) | HTTEPHX2NAAACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263794-B2 | Process for the partial hydrogenation of fatty acid esters | COGNIS IP MANAGEMENT GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20100022664-A1 | Process for the partial hydrogenation of fatty acid esters | COGNIS IP MANAGEMENT GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022664-A1 | Process for the partial hydrogenation of fatty acid esters | ELOVL3, LIPA, FFAR2 | EPHX1 555/4885ALDH1A1 1587/4885HTT 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.